A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

British Journal of Cancer

Volumn 114, Issue 8, 2016, Pages 889-896

  Mateo, Joaquin ^a   Olmos, David ^a,b   Dumez, Herlinde ^c   Poondru, Srinivasu ^d   Samberg, Nancy L ^d   Barr, Sharon ^d   Van Tornout, Jan M ^d   Jie, Fei ^d   Sandhu, Shahneen ^a   Tan, Daniel S ^a   Moreno, Victor ^a   Lo Russo, Patricia M ^e   Kaye, Stan B ^a   Schöffski, Patrick ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Structural Biology and Biocomputing Programme   (Spain)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^e YALE UNIVERSITY   (United States)

Author keywords

first in man; mTORC1 2; pharmacodynamics; pharmacokinetics; phase I clinical trial

Indexed keywords

4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; CREATINE KINASE; CREATININE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; IMIDAZOLE DERIVATIVE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; TRIAZINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BACKACHE; BONE PAIN; CANCER PATIENT; CARDIOMYOPATHY; CARDIOTOXICITY; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONSTIPATION; COUGHING; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; TAKOTSUBO CARDIOMYOPATHY; TUMOR BIOPSY; URTICARIA; VOMITING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HALF LIFE TIME; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MONONUCLEAR CELL; NEOPLASMS; PATHOLOGY; YOUNG ADULT;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; IMIDAZOLES; LEUKOCYTES, MONONUCLEAR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; NEOPLASMS; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES; TRIAZINES; YOUNG ADULT;

EID: 84961393725     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.59     Document Type: Article

References (24)

1. Baselga J, Campone M, Piccart M, Burris 3rd HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. (2012). Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. N Engl J Med 366: 520-529
2. Basu B, Dean E, Puglisi M, Greystoke A, Ong M, Burke W, Cavallin M, Bigley G, Womack C, Harrington EA, Green S, Oelmann E, de Bono JS, Ranson M, Banerji U. (2015). First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor, AZD2014. Clin Cancer Res 21(34): 3412-3419
3. Becker MN, Wu KJ, Marlow LA, Kreinest PA, Vonroemeling CA, Copland JA, Williams CR. (2014). The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro. Urol Oncol 32(3): 317-326
4. Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, Epstein DM, Gibson NW, Wild R, Arnold LD, Houghton PJ, Pachter JA. (2011). Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther 10(8): 1394-1406
5. CinàDP, Onay T, Paltoo A, Li C, Maezawa Y, De Arteaga J, Jurisicova A, Quaggin SE. (2012). Inhibition of MTOR disrupts autophagic flux in podocytes. J Am Soc Nephrol 23(3): 412-420
6. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL. (2008). Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS medicine 5(1): e8
7. Dote K, Sato H, Tateishi H, Uchida T, Ishihara M. (1991). Myocardial stunning due to simultaneous multivessel coronary spasms: a review of 5 cases. J Cardiol 21(2): 203-214
8. Falcon BL, Barr S, Gokhale PC, Chou J, Fogarty J, Depeille P, Miglarese M, Epstein DM, McDonald DM. (2011). Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res 71(5): 1573-1583
9. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. (2009). Active-site inhibitors of mTOR target rapamycinresistant outputs of mTORC1 and mTORC2. PLoS Biology 7(2): e38
10. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O Toole T, Lustgarten S, Moore L, Motzer RJ. Global ARCC Trial. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Eng J Med 356(22): 2271-2281
11. Izzedine H, Escudier B, Rouvier P, Gueutin V, Varga A, Bahleda R, Soria JC. (2013). Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven. Ann Oncol 24(9): 2421-2425
12. Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A, Hall MN. (2004). Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6(11): 1122-1128
13. Lieberthal W, Levine JS. (2012). Mammalian target of rapamycin and the kidney. I. The signaling pathway. Am J Physiol Renal Physiol 303(1): F1-F10
14. De Masson A, Fouchard N, Méry-Bossard L, Dauendorffer JN. (2011). Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors. Dermatology 223(1): 4-8
15. Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, Fischer PM, Trinos MJ, Patil S, Motzer RJ. (2011). Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 118(7): 1868-1876
16. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. RECORD-1 Study Group. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637): 449-456
17. Naing A, Aghajanian C, Raymond E, Olmos D, Schwartz G, Oelmann E, Grinsted L, Burke W, Taylor R, Kaye S, Kurzrock R, Banerji U. (2012). Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer 107(7): 1093-1099
18. Qasem A, Bin Abdulhak AA, Aly A, Moormeier J. (2014). Capecitabineinduced takotsubo cardiomyopathy: a case report and literature review. Am J Ther. e-pub ahead of print 29 December 2015
19. Sabatini DM. (2006). mTOR and cancer: insight into a complex relationship. Nat Rev Cancer 6(9): 729-734
20. Sonis S, Treister N, Chawla S, Demetri G, Haluska F. (2010). Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 116(1): 210-215
21. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J. (2008). Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26(10): 1603-1610
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. (2000). New Guidelines to Evaluate the Response to Treatment. J Natl Cancer Inst 92(3): 205-216
23. Wilson-Edell KA, Yevtushenko MA, Rothschild DE, Rogers AN, Benz CC. (2014). mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms. Breast Cancer Res Treat 144(2): 287-298
24. Yao J, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K. RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. (2011). Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6): 514-523